EpiGeneer

RESTORING MYELIN · MULTIPLE SCLEROSIS

Be Part of EpiGeneer

The Investment Opportunity

An Afternoon with EpiGeneer · Basel, 9 October 2026

Where Your Investment Goes

EpiGeneer

AdRegeneer AG Basel

Epigenetic platform

100% owner

EpiGeneer GmbH Mainz

The MS transdermal patch



You invest here

Focus

One asset: the MS patch

Exit potential


Simpler to partner, license or sell

Funding

Claire is a professor at JGU Mainz, opening doors to German and EU grants

Where We Stand

EpiGeneer



Funding Secured so Far

EpiGeneer

€1.84M

secured so far

GRANTS AND DONATIONS
€1.44M

€1.16M	Else Kröner Fresenius Foundation
€140k	Mainzer Wissenschaftsstiftung
€70k	Patient donations
€30k	Innosuisse Core Coaching
€10k	Innosuisse Initial Coaching
€30k	JGU Mainz

PRIVATE €400k

€300k	Thomas Meier
€100k	Giuseppe Botte

Years

of our own time

How The SAFE Works

EpiGeneer

Simple Agreement for Future Equity: invest now, become a shareholder later.

You invest now

into EpiGeneer GmbH

Next round

at least €1M, or within 36 months

You become a shareholder

at a company value of €15M at most

Your protections

€15M cap

your price never goes above it

MFN

better economic terms apply to you

Pro-rata

keep your stake later


Acquisition

share in the proceeds

Your Potential

EpiGeneer

ILLUSTRATIVE · €100,000 AT THE €15M CAP



The Round

EpiGeneer

The science is funded until the end of Phase I. You invest in the company around it.

€15M	€250k	€25k to €100k
valuation cap	target today	per ticket

First investor of this round already confirmed

Where The Money Goes

EpiGeneer

How we use this round.

40%
Patents

20%
People

20%
Development and regulatory

20%
Running the company

This round covers our runway until the end of Phase I, and brings us one step closer to the patients.

Next steps: the SAFE is here for you today · we answer all your questions

Why a €15M Cap?

EpiGeneer

Your conversion cap

€15M

Our model, depending on the scenario

€25 to 50M

Factors in the probability of success at each clinical stage.

First in a big field

MS is a large market, and our approach to myelin repair is new.

Lower risk, lower cost

A new mechanism in an innovative delivery. Phase I and II cost far less than for a new molecule.

Angels before VCs


VCs price the average. We chose an attractive deal for angels over an undervalued VC deal.

Internal business model, updated estimate of the value of the patch program, weighted by the probability of success at each stage. Based on assumptions about timelines, clinical outcomes and the market. Not an independent valuation.

How The Conversion Works

EpiGeneer

ILLUSTRATIVE



Illustrative paper values at the new round's price. Not an offer of securities.